Amarin's (NASDAQ:AMRN) share price has yo-yoed after the company gained Food and Drug Administration approval for its triglyceride-lowering drug, Vascepa, this summer. However, investors are still interested in this exciting biotech story, and there are reasons to be both bullish and bearish on this stock.

In the following video, Austin Smith talks with health care analyst and author of our premium research report on Amarin, Max Macaluso, about one specific reason to buy shares of this company and one reason to sell.

Austin Smith has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.